G
Guy van Hazel
Researcher at University of Western Australia
Publications - 61
Citations - 8529
Guy van Hazel is an academic researcher from University of Western Australia. The author has contributed to research in topics: Colorectal cancer & Oxaliplatin. The author has an hindex of 25, co-authored 57 publications receiving 7931 citations. Previous affiliations of Guy van Hazel include University of Sydney & Sir Charles Gairdner Hospital.
Papers
More filters
Journal ArticleDOI
Cetuximab for the Treatment of Colorectal Cancer
Derek J. Jonker,Christopher J. O'Callaghan,Christos S. Karapetis,John Zalcberg,Dongsheng Tu,Heather-Jane Au,Scott R. Berry,Marianne Krahn,Timothy J. Price,R. John Simes,Niall C. Tebbutt,Guy van Hazel,Rafal Wierzbicki,Christiane Langer,Malcolm J. Moore +14 more
TL;DR: Cetuximab improves overall survival and progression-free survival and preserves quality-of-life measures in patients with colorectal cancer in whom other treatments have failed.
Journal ArticleDOI
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen
Eric Van Cutsem,Josep Tabernero,Radek Lakomy,Hans Prenen,Jana Prausová,Teresa Macarulla,Paul Ruff,Guy van Hazel,Vladimir Moiseyenko,David R. Ferry,Joseph McKendrick,J. Polikoff,Alexia Tellier,Remi Castan,Carmen J. Allegra +14 more
TL;DR: Adverse effects reported with aflibercept combined with FOLFIRI included the characteristic anti-vascular endothelial growth factor effects and also reflected an increased incidence of some chemotherapy-related toxicities.
Journal ArticleDOI
Capecitabine as Adjuvant Treatment for Stage III Colon Cancer
Chris Twelves,A. Wong,M. Nowacki,Markus Abt,Howard A. Burris,Alfredo Carrato,Jim Cassidy,Andrés Cervantes,Jan Fagerberg,Vassilis Georgoulias,Fares Husseini,Duncan I. Jodrell,P. Koralewski,Hendrik Kröning,Jean A. Maroun,Norbert Marschner,Joseph McKendrick,M. Pawlicki,Riccardo Rosso,Johannes Schüller,Jean-François Seitz,Borut Stabuc,Jerzy Tujakowski,Guy van Hazel,Jerzy Zaluski,Werner Scheithauer +25 more
TL;DR: Oral capecitabine is an effective alternative to intravenous fluorouracil plus leucovorin in the adjuvant treatment of colon cancer.
Journal ArticleDOI
Superior Survival With Capecitabine Plus Docetaxel Combination Therapy in Anthracycline-Pretreated Patients With Advanced Breast Cancer: Phase III Trial Results
Joyce A. O'Shaughnessy,David Miles,Svetislava J. Vukelja,Vladimir Moiseyenko,Jean-Pierre M. Ayoub,Guadalupe Cervantes,Pierre Fumoleau,Stephen E. Jones,Wing-Yiu Lui,Louis Mauriac,Chris Twelves,Guy van Hazel,Shailendra Verma,Robert C. F. Leonard +13 more
TL;DR: The significantly superior TTP and survival achieved with the addition of capecitabine to docetaxel 75 mg/m(2), with the manageable toxicity profile, indicate that this combination provides clear benefits over single-agent docetAXel 100 mg/ m(2).
Journal ArticleDOI
Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer.
Guy van Hazel,Anthony Blackwell,James E.M. Anderson,David H. Price,Paul Moroz,Geoff Bower,Giuseppe Cardaci,Bruce N. Gray +7 more
TL;DR: This randomised trial was designed to presage a larger trial that would have survival as the primary outcome and compare the response rate, time to progressive disease, and toxicity of a regimen of systemic fluorouracil/leucovorin chemotherapy versus the same chemotherapy plus a single administration of SIR‐Spheres in patients with advanced colorectal liver metastases.